A detailed history of Bank Julius Baer & Co. Ltd, Zurich transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Julius Baer & Co. Ltd, Zurich holds 107,989 shares of REGN stock, worth $81.7 Million. This represents 0.44% of its overall portfolio holdings.

Number of Shares
107,989
Previous 112,948 4.39%
Holding current value
$81.7 Million
Previous $119 Million 4.37%
% of portfolio
0.44%
Previous 0.5%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1024.09 - $1201.76 $5.08 Million - $5.96 Million
-4,959 Reduced 4.39%
107,989 $114 Million
Q2 2024

Aug 14, 2024

SELL
$883.2 - $1071.19 $4.36 Million - $5.28 Million
-4,933 Reduced 4.18%
112,948 $119 Million
Q1 2024

May 14, 2024

BUY
$902.69 - $993.35 $26 Million - $28.6 Million
28,826 Added 32.37%
117,881 $113 Million
Q4 2023

May 16, 2024

SELL
$775.18 - $881.7 $89.7 Million - $102 Million
-115,665 Reduced 98.12%
2,216 $1.95 Million
Q4 2023

May 16, 2024

BUY
$775.18 - $881.7 $67.3 Million - $76.6 Million
86,839 Added 3918.73%
89,055 $78.2 Million
Q4 2023

Feb 02, 2024

BUY
$775.18 - $881.7 $3.84 Million - $4.37 Million
4,954 Added 5.89%
89,055 $78.2 Million
Q3 2023

Nov 13, 2023

BUY
$692.45 - $844.37 $6.2 Million - $7.55 Million
8,947 Added 11.9%
84,101 $69.2 Million
Q2 2023

Jul 24, 2023

BUY
$700.03 - $830.35 $52.6 Million - $62.4 Million
75,154 New
75,154 $54 Million
Q1 2023

May 11, 2023

BUY
$680.49 - $826.97 $4.93 Million - $5.99 Million
7,246 Added 9.77%
81,434 $66.9 Million
Q4 2022

Jan 24, 2023

SELL
$705.89 - $766.39 $19.4 Million - $21.1 Million
-27,470 Reduced 27.02%
74,188 $53.5 Million
Q3 2022

Nov 04, 2022

BUY
$573.97 - $724.32 $237,049 - $299,144
413 Added 0.41%
101,658 $70 Million
Q2 2022

Jul 22, 2022

BUY
$548.35 - $738.84 $54.6 Million - $73.5 Million
99,535 Added 5820.76%
101,245 $59.8 Million
Q1 2022

May 09, 2022

BUY
$595.12 - $698.43 $704,026 - $826,242
1,183 Added 224.48%
1,710 $1.19 Million
Q4 2021

Feb 15, 2022

SELL
$543.48 - $670.97 $4,347 - $5,367
-8 Reduced 1.5%
527 $333,000
Q3 2021

Nov 12, 2021

SELL
$574.03 - $680.96 $167,616 - $198,840
-292 Reduced 35.31%
535 $324,000
Q2 2021

Jul 23, 2021

BUY
$472.8 - $558.54 $36,405 - $43,007
77 Added 10.27%
827 $462,000
Q1 2021

May 10, 2021

SELL
$446.73 - $548.2 $49,587 - $60,850
-111 Reduced 12.89%
750 $355,000
Q4 2020

Feb 24, 2021

SELL
$478.3 - $607.98 $874,332 - $1.11 Million
-1,828 Reduced 67.98%
861 $416,000
Q4 2020

Feb 12, 2021

BUY
$478.3 - $607.98 $945,120 - $1.2 Million
1,976 Added 277.14%
2,689 $416,000
Q3 2020

Nov 10, 2020

SELL
$544.75 - $658.21 $525,683 - $635,172
-965 Reduced 57.51%
713 $399,000
Q2 2020

Aug 12, 2020

BUY
$493.32 - $643.92 $827,790 - $1.08 Million
1,678 New
1,678 $1.05 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $81.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Bank Julius Baer & Co. Ltd, Zurich Portfolio

Follow Bank Julius Baer & Co. Ltd, Zurich and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

News

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.